Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03977259

Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development

This study is a randomized trial comparing 2 methods of human milk fortification for preterm infants in the neonatal intensive care unit (NICU). All participating infants will receive a human milk diet comprising maternal and/or donor milk plus multi-component and modular fortifiers. In one group (control), the milk will be fortified according to routine standard of care. In the other group (intervention), the fortification will be individually targeted based on the results of point-of-care human milk analysis. Outcomes include physical growth in the NICU and after discharge, brain structure by magnetic resonance imaging at term equivalent age, and neurodevelopment at 2 years.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

About this study

Human milk is the recommended diet for preterm infants and it requires fortification to meet their high nutrient requirements. This study addresses a gap in knowledge about the optimal strategy for human milk fortification in the neonatal intensive care unit (NICU).

Infants will be recruited from a single site (Brigham and Women's Hospital, Boston MA). Eligible infants are NICU inpatients born <31 weeks' gestation and enrolled within 21 days of birth, whose mothers are providing breast milk. Exclusion criteria include major congenital anomalies, severe fetal growth restriction (weight <3rd percentile), clinically significant gastrointestinal pathology, triplets or higher order multiples, and expected death or transfer. Infants who require fluid restriction <140 mL/kg/day will also be excluded.

The study period begins when infants have reached full volume (150-160 mL/kg/day) human milk feedings fortified to 24 kcal per ounce. Participants will be randomized to one of two diet groups; twins will be randomized separately. The study diet will continue until 36 weeks' postmenstrual age or hospital discharge, whichever comes first.

Available maternal milk will be pooled with donor milk (if needed) to reach the total daily fluid volume; this "base" milk will be analyzed with a point-of-care human milk analyzer (Miris, AB). All infants will receive at minimum the standard human milk fortification (multicomponent fortifier to 24 kcal/oz plus liquid protein 0.27 g/dL). In one group (control), we will follow the standard of care for milk fortification, only adding more protein and/or energy if weight gain is lagging. In the other group (intervention), we will individually target fortification with additional protein and/or energy so that the "base" milk always contains protein 1 g/dL and energy 67 kcal/dL.

Outcome measures will include physical growth during the diet intervention period, including gain in weight, length, and head circumference and body composition with air displacement plethysmography at the end of the diet intervention. At term equivalent age, participants will undergo brain magnetic resonance imaging. At 2 years corrected age, outcomes include standard and novel neurodevelopmental tests including the Bayley-III and tests of emerging executive function; and physical size.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inpatient in Brigham and Women's Hospital NICU
  • Gestational age 24 0/7 to 30 6/7 weeks
  • Chronologic age <21 days
  • Mother providing breast milk

Exclusion criteria

  • Major congenital anomaly
  • Severe fetal growth restriction (birth weight <3rd percentile by Olsen reference)
  • Necrotizing enterocolitis, intestinal perforation, other major gastrointestinal pathology
  • Triplets or higher order multiples
  • Plan for redirection of care and/or anticipated death
  • Clinically significant renal or hepatic dysfunction
  • Inborn error of metabolism
  • Fluid restriction <140 mL/kg/day for 3 or more days
  • Grade 3 or 4 intraventricular hemorrhage detected prior to enrollment
  • Anticipated transfer <36 weeks' postmenstrual age
  • Parents do not consent to use of pasteurized donor human milk
  • Infant in non-parental custody

Treatment and study plan

Individually targeted fortification

Other

Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the "base" milk has protein 1 g/dL and calories 67/dL.

Primary outcomes

  1. Weight

    Time frame: at study endpoint (36 weeks' postmenstrual age or discharge)

    Weight z-score

  2. Length

    Time frame: at study endpoint (36 weeks' postmenstrual age or discharge)

    Length z-score

  3. Fat free mass

    Time frame: at study endpoint (36 weeks' postmenstrual age or discharge)

    Fat free mass estimated with air displacement plethysmography (z-score)

  4. Total brain volume

    Time frame: at term equivalent age (38 to 41 weeks' postmenstrual age)

    Total brain volume by MRI

  5. Cerebellar volume

    Time frame: at term equivalent age (38 to 41 weeks' postmenstrual age)

    Cerebellar volume by MRI

  6. Bayley-III cognitive score

    Time frame: at 2 years' corrected age

    Scaled composite score (continuous), higher score indicates better performance, range of possible scores 55-145

  7. Bayley-III motor score

    Time frame: at 2 years' corrected age

    Scaled composite score (continuous), higher score indicates better performance, range of possible scores 46-154

Secondary outcomes

  1. Fat mass

    Time frame: at study endpoint (36 weeks' postmenstrual age or discharge)

    Fat mass estimated with air displacement plethysmography (z-score)

  2. Weight

    Time frame: at 2 years' corrected age

    Weight z-score

  3. Height

    Time frame: at 2 years' corrected age

    Height z-score

  4. Low Bayley-III cognitive score

    Time frame: At 2 years' corrected age

    Scaled composite score <85 (>1 standard deviation below the normative mean)

  5. Low Bayley-III motor score

    Time frame: At 2 years' corrected age

    Scaled composite score <85 (>1 standard deviation below the normative mean)

  6. Bayley-III language score

    Time frame: At 2 years' corrected age

    Scaled composite score (continuous), higher score indicates better performance, range of possible scores 46-154

  7. Bayley-III language score

    Time frame: At 2 years' corrected age

    Scaled composite score <85 (>1 standard deviation below the normative mean)

  8. Spacial working memory

    Time frame: at 2 years' corrected age

    Spin the Pots task (number of trials, search time)

  9. Behavioral inhibition

    Time frame: at 2 years' corrected age

    Mommies and Babies task (number of trials, errors)

  10. Executive function

    Time frame: at 2 years' corrected age

    Behavioral Rating Inventory of Executive Function - Preschool Version, higher scores indicate more problems

  11. Behavioral difficulties

    Time frame: at 2 years' corrected age

    Infant-Toddler Symptom Checklist - Long Version, higher scores indicate more problems

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Registry information

Important dates

Study start
2020
Primary completion
2027
Study completion
2030
First posted
Jun 6, 2019
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.